Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Intra-Cellular Therapies Inc. - Common Stock
(NQ:
ITCI
)
131.37
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intra-Cellular Therapies Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
March 07, 2025
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
Via
Benzinga
Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday
February 24, 2025
Via
Benzinga
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
February 24, 2025
Via
Benzinga
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
February 21, 2025
Via
Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
February 18, 2025
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.
Via
Benzinga
Exposures
Product Safety
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
January 22, 2025
Via
Benzinga
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
November 04, 2024
Via
Benzinga
Earnings Preview For Intra-Cellular Therapies
October 29, 2024
Via
Benzinga
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
January 22, 2025
Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts.
Via
Benzinga
Top 4 Health Care Stocks You May Want To Dump In Q1
January 21, 2025
Via
Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
January 19, 2025
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals.
Via
Benzinga
MarketBeat Week in Review – 01/13 - 01/17
January 18, 2025
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally
Via
MarketBeat
Topics
Economy
Energy
Exposures
Fossil Fuels
Interest Rates
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
October 04, 2024
Via
Benzinga
Expert Ratings For Intra-Cellular Therapies
September 06, 2024
Via
Benzinga
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
January 17, 2025
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
January 17, 2025
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive
Via
MarketBeat
Exposures
Product Safety
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
January 13, 2025
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.
Via
Benzinga
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
January 13, 2025
Via
Benzinga
Nasdaq, S&P 500 Fall As Bond Yields Pressure Tech Stocks
January 13, 2025
Stocks are a mixed bag to start the week.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Exposures
US Equities
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
January 13, 2025
Via
Benzinga
Exposures
Fossil Fuels
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
January 13, 2025
Via
Benzinga
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
January 13, 2025
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.
Via
Benzinga
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
January 13, 2025
The deal values the smaller biotech company at a 39% premium to last week's closing price.
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
January 13, 2025
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million...
Via
Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 13, 2025
Via
Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
January 13, 2025
Via
Benzinga
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
January 12, 2025
Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United...
Via
Benzinga
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
December 31, 2024
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.
Via
Benzinga
Exposures
Product Safety
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
November 05, 2024
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile.
Via
Benzinga
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
September 06, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.